A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Corvus Pharmaceuticals Inc’s current trading price is -0.33% away from its 52-week high, while its distance from the 52-week low is 184.76%. The stock’s price range for this time frame has been between $1.05 and $3.00. The trading volume of the company’s shares in the Healthcare reached around 0.69 million for the day, which was evidently higher than the average daily volume of 0.23 million over the last three months.
Corvus Pharmaceuticals Inc had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $3.00 on 07/30/24, while the lowest price during the same period was $1.05 on 10/30/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Corvus Pharmaceuticals Inc (CRVS) has experienced a quarterly rise of 85.71% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 187.02M and boasts a workforce of 28 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.94, with a change in price of +0.87. Similarly, Corvus Pharmaceuticals Inc recorded 218,860 in trading volume during the last 100 days, posting a change of +41.04%.
How CRVS’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for CRVS stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.00.
CRVS Stock Stochastic Average
The raw stochastic average for Corvus Pharmaceuticals Inc over the last 50 days is presently at 99.20%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 99.20%. Further, the company’s Stochastic %K and %D values for the last 20 days were 78.67% and 81.26%, respectively.
CRVS Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The index has shown a price gain of 69.89% this year. Over the last six months, there has been a weaker performance of 49.50%. The price of CRVS fallen by 67.98% during the last 30 days period. For the last 5-days stocks have improved 29.44%.
